242 related articles for article (PubMed ID: 7965756)
21. First-pass midazolam metabolism catalyzed by 1alpha,25-dihydroxy vitamin D3-modified Caco-2 cell monolayers.
Fisher JM; Wrighton SA; Watkins PB; Schmiedlin-Ren P; Calamia JC; Shen DD; Kunze KL; Thummel KE
J Pharmacol Exp Ther; 1999 May; 289(2):1134-42. PubMed ID: 10215697
[TBL] [Abstract][Full Text] [Related]
22. In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies.
Prueksaritanont T; Kuo Y; Tang C; Li C; Qiu Y; Lu B; Strong-Basalyga K; Richards K; Carr B; Lin JH
Drug Metab Dispos; 2006 Sep; 34(9):1546-55. PubMed ID: 16782766
[TBL] [Abstract][Full Text] [Related]
23. Cytochrome P450-dependent metabolism of midazolam in hepatic microsomes from chickens, turkeys, pheasant and bobwhite quail.
Cortright KA; Craigmill AL
J Vet Pharmacol Ther; 2006 Dec; 29(6):469-76. PubMed ID: 17083450
[TBL] [Abstract][Full Text] [Related]
24. Probe of CYP3A by a single-point blood measurement after oral administration of midazolam in healthy elderly volunteers.
Krupka E; Venisse N; Lafay C; Gendre D; Diquet B; Bouquet S; Perault MC
Eur J Clin Pharmacol; 2006 Aug; 62(8):653-9. PubMed ID: 16832678
[TBL] [Abstract][Full Text] [Related]
25. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.
Perloff MD; von Moltke LL; Court MH; Kotegawa T; Shader RI; Greenblatt DJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):618-28. PubMed ID: 10640299
[TBL] [Abstract][Full Text] [Related]
26. Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans.
Klieber S; Hugla S; Ngo R; Arabeyre-Fabre C; Meunier V; Sadoun F; Fedeli O; Rival M; Bourrie M; Guillou F; Maurel P; Fabre G
Drug Metab Dispos; 2008 May; 36(5):851-62. PubMed ID: 18256203
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression.
Pinto AG; Wang YH; Chalasani N; Skaar T; Kolwankar D; Gorski JC; Liangpunsakul S; Hamman MA; Arefayene M; Hall SD
Clin Pharmacol Ther; 2005 Mar; 77(3):178-88. PubMed ID: 15735612
[TBL] [Abstract][Full Text] [Related]
28. Cooperative binding of midazolam with testosterone and alpha-naphthoflavone within the CYP3A4 active site: a NMR T1 paramagnetic relaxation study.
Cameron MD; Wen B; Allen KE; Roberts AG; Schuman JT; Campbell AP; Kunze KL; Nelson SD
Biochemistry; 2005 Nov; 44(43):14143-51. PubMed ID: 16245930
[TBL] [Abstract][Full Text] [Related]
29. The structural basis for homotropic and heterotropic cooperativity of midazolam metabolism by human cytochrome P450 3A4.
Roberts AG; Yang J; Halpert JR; Nelson SD; Thummel KT; Atkins WM
Biochemistry; 2011 Dec; 50(50):10804-18. PubMed ID: 21992114
[TBL] [Abstract][Full Text] [Related]
30. Rapid and simultaneous measurement of midazolam, 1'-hydroxymidazolam and digoxin by liquid chromatography/tandem mass spectrometry: application to an in vivo study to simultaneously measure P-glycoprotein and cytochrome P450 3A activity.
Xue X; Huang M; Xiao H; Qin X; Huang L; Zhong G; Bi H
J Pharm Biomed Anal; 2011 Apr; 55(1):187-93. PubMed ID: 21316177
[TBL] [Abstract][Full Text] [Related]
31. Sex-dependent differences in cytochrome P450 3A activity as assessed by midazolam disposition in humans: a meta-analysis.
Hu ZY; Zhao YS
Drug Metab Dispos; 2010 May; 38(5):817-23. PubMed ID: 20164111
[TBL] [Abstract][Full Text] [Related]
32. Nutritional Status Differentially Alters Cytochrome P450 3A4 (CYP3A4) and Uridine 5'-Diphospho-Glucuronosyltransferase (UGT) Mediated Drug Metabolism: Effect of Short-Term Fasting and High Fat Diet on Midazolam Metabolism.
Lammers LA; Achterbergh R; Romijn JA; Mathôt RAA
Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):751-767. PubMed ID: 29876844
[TBL] [Abstract][Full Text] [Related]
33. Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone.
Miyazaki M; Nakamura K; Fujita Y; Guengerich FP; Horiuchi R; Yamamoto K
Drug Metab Dispos; 2008 Nov; 36(11):2287-91. PubMed ID: 18669585
[TBL] [Abstract][Full Text] [Related]
34. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.
Thummel KE; O'Shea D; Paine MF; Shen DD; Kunze KL; Perkins JD; Wilkinson GR
Clin Pharmacol Ther; 1996 May; 59(5):491-502. PubMed ID: 8646820
[TBL] [Abstract][Full Text] [Related]
35. Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.
Woolsey SJ; Beaton MD; Choi YH; Dresser GK; Gryn SE; Kim RB; Tirona RG
Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):284-91. PubMed ID: 26399557
[TBL] [Abstract][Full Text] [Related]
36. Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat.
Eeckhoudt SL; Horsmans Y; Verbeeck RK
Xenobiotica; 2002 Nov; 32(11):975-84. PubMed ID: 12487727
[TBL] [Abstract][Full Text] [Related]
37. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
38. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models.
Vossen M; Sevestre M; Niederalt C; Jang IJ; Willmann S; Edginton AN
Theor Biol Med Model; 2007 Mar; 4():13. PubMed ID: 17386084
[TBL] [Abstract][Full Text] [Related]
39. Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping.
Streetman DS; Kashuba AD; Bertino JS; Kulawy R; Rocci ML; Nafziger AN
Pharmacogenetics; 2001 Jun; 11(4):349-55. PubMed ID: 11434513
[TBL] [Abstract][Full Text] [Related]
40. Drug-drug interactions and metabolism in cytochrome P450 2C knockout mice: application to troleandomycin and midazolam.
Grimsley A; Gallagher R; Hutchison M; Pickup K; Wilson ID; Samuelsson K
Biochem Pharmacol; 2013 Aug; 86(4):529-38. PubMed ID: 23732297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
